Effect of antilipemic therapy with rosuvastatin and ezetimibe on cholesterol metabolism markers in patients with coronary atherosclerotic heart disease
Zheng Hong
Mi Shuhua
Zhang Tao
Yang Hongxia
Su Gong
Zhang Xiaoxia
Abstract：Objective To explore the effect of antilipemic therapy of rosuvastatin combined with ezetimibe on cholesterol metabolism markers in patients with coronary atherosclerotic heart disease(CHD).Methods Totally 104 patients with CHD from January 2014 to June 2015 in Beijing Anzhen Hospital,Capital Medical University were enrolled.After 4 weeks of treatment with atorvastatin,all patients were divided into blood lipid attainment group (75cases) and blood lipid non-attainment group (29 cases).Blood lipid attainment group was treated with rosuvastatin for next 8 weeks,blood lipid non-attainment group was treated with rosuvastatin and ezetimibe for next 8 weeks.Concentrations of blood lipid,cholesterol synthesis markers and cholesterol absorption markers were measured before treatment and after 4,12 weeks of treatment.Results ①In all of 104 CHD patients,total cholesterol(TC) level,low-density lipoprotein cholesterol (LDL-C) level and the absolute value of lathosterol after 4 weeks of treatment were significantly lower than those before treatment,the specific value of sitosterol/TC after 4 weeks of treatment was significantly lower than that before treatment [(3.20 ± 0.14) mmol/L vs (4.41 ± 1.23) mmol/L,(2.03 ±0.12)mmol/Lvs (2.92 ± 0.20) mmol/L,(13.3±2.0)mg/L vs (16.1 ±2.9)mg/L,(10.4±0.8)mg/g vs (8.8 ±0.6) mg/g] (P ＜ 0.05).②In blood lipid attainment group,differences of TC,LDL-C and cholesterol metabolism markers were not significant between values after 12 weeks of treatment and those after 4 weeks of treatment(P ＞0.05).③In blood lipid non-attainment group,TC,LDL-C,campesterol,sitosterol and campesterol/TCafter 12 weeks of treatment were significantly lower than those after 4 weeks of treatment[(2.65 ± 0.23) mmol/L vs(3.28 ±0.17) mmol/L,(2.03 ± 0.09) mmol/L vs (2.40 ± 0.11) mmol/L,(4.2 ± 0.5) mg/L vs (7.0 ±0.9)mg/L,(12.1 ±1.1)mg/L vs (14.3 ± 1.2)mg/L,(3.2 ±0.4)mg/g vs (5.2 ±0.4) mg/g] (all P ＜0.05).Conclusion Antilipemic therapy combination of rosuvastatin and ezetimibe can reduce cholesterol absorption and further lower the level of thod lipid.
Keywords：Coronary atherosclerotic heart diseaseCholesterol matabolism markersAntilipemic therapy
Publication Date：2016-09-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1265-1269 )